LMDA Review, volume 12, issue 1

Contents include: Re-Viewing Denver, University & Student Caucus, Keynote Ashara Ekundayo, Denver Theatre Artists on Local Theatre Ecology, Workshop Sessions Round 1: Dramaturgy & Architecture, Dramaturgical Voices Inside the Theatre, Dramaturgy/Making a Life, Workshop Sessions Round 2: New Play Festivals, Dramaturgical Voices Outside the Theatre, Educational Theatre, TheatreFest Playwrights, Advocacy, Elliott Hayes Award Winner Judith Rudakoff, and Regional VP Update.https://soundideas.pugetsound.edu/lmdareview/1024/thumbnail.jp

Review: The Newsletter of Literary Managers and Dramaturgs of the Americas, volume 11, issue 3

Contents include: Section I: Re-Viewing Denver; The Conference in Detail; Dramaturgical Voices Outside the Theatre; Section II: Articles & Announcements. Issue editor: Gretchen Haleyhttps://soundideas.pugetsound.edu/lmdareview/1048/thumbnail.jp

Psychological treatments for the management of pain following musculoskeletal injury:a systematic review and meta-analysis

Musculoskeletal injury is a leading cause of pain and disability worldwide; 35-75% of people experience persistent pain for months and years after injury. Psychological treatments can reduce pain, functional impairment and psychological distress, but are not widely utilized following injury. This systematic review and meta-analysis (PROSPERO ID: CRD42021236807) aimed to synthesize the literature testing psychological treatments for pain following musculoskeletal injury. We searched EMBASE, MEDLINE, PubMed, PsycINFO, and CENTRAL from inception to May 2022. We extracted participant, treatment, and injury characteristics, and primary (e.g., pain intensity, functional impairment, depression, anxiety, PTSD symptoms) and secondary (treatment feasibility and acceptability) outcomes. 24 RCTs (N = 1,966) were included. Immediately post-treatment, people who received psychological treatments (versus any control) reported lower pain intensity (SMD = -0.25, 95% CI [-0.49, -0.02]), functional impairment (SMD = -0.32 [-0.55, -0.09]), and symptoms of depression (SMD = -0.46 [-0.64, -0.29]), anxiety (SMD = -0.34 [-0.65, -0.04]) and PTSD (SMD = -0.43 [-0.70, -0.15]); at 6-month follow-up, only depression symptoms were significantly lower. Included trials varied widely in treatment and injury characteristics. The certainty of evidence was low or very low for most effects, and heterogeneity moderate to substantial. Most studies had risk of bias domains judged to be high or unclear. Due to very low certainty of results, we are unsure whether psychological therapies reduce pain and functional impairment following musculoskeletal injury; they may result in improved depression immediately post-treatment and at follow-up. More research is needed to identify treatments that result in enduring effects

Psychological treatments for the management of pain following musculoskeletal injury:a systematic review and meta-analysis

Musculoskeletal injury is a leading cause of pain and disability worldwide; 35-75% of people experience persistent pain for months and years after injury. Psychological treatments can reduce pain, functional impairment and psychological distress, but are not widely utilized following injury. This systematic review and meta-analysis (PROSPERO ID: CRD42021236807) aimed to synthesize the literature testing psychological treatments for pain following musculoskeletal injury. We searched EMBASE, MEDLINE, PubMed, PsycINFO, and CENTRAL from inception to May 2022. We extracted participant, treatment, and injury characteristics, and primary (e.g., pain intensity, functional impairment, depression, anxiety, PTSD symptoms) and secondary (treatment feasibility and acceptability) outcomes. 24 RCTs (N = 1,966) were included. Immediately post-treatment, people who received psychological treatments (versus any control) reported lower pain intensity (SMD = -0.25, 95% CI [-0.49, -0.02]), functional impairment (SMD = -0.32 [-0.55, -0.09]), and symptoms of depression (SMD = -0.46 [-0.64, -0.29]), anxiety (SMD = -0.34 [-0.65, -0.04]) and PTSD (SMD = -0.43 [-0.70, -0.15]); at 6-month follow-up, only depression symptoms were significantly lower. Included trials varied widely in treatment and injury characteristics. The certainty of evidence was low or very low for most effects, and heterogeneity moderate to substantial. Most studies had risk of bias domains judged to be high or unclear. Due to very low certainty of results, we are unsure whether psychological therapies reduce pain and functional impairment following musculoskeletal injury; they may result in improved depression immediately post-treatment and at follow-up. More research is needed to identify treatments that result in enduring effects

LMDA Review, volume 8, issue 2 (sic)

Contents include: Editor\u27s Note, Notes from the President, Four Dramturgs for Dramaturgs, Jon Jory: An Editorial Response/Current Issues in Dramaturgy, and Anne Bogart: Dramaturging the Audience. Issue editors: Michael Bigelow Dixon, Amy Wegenerhttps://soundideas.pugetsound.edu/lmdareview/1017/thumbnail.jp

Review: The Newsletter of the Literary Managers and Dramaturgs of the Americas, volume 16, issue 2

Contents include: Driving, LMDA Conference 2006: Think Dramaturgically, Act Locally, Words of Welcome from the Conference Committee, Developing a Sense of Community: Reflections on the Balance of a Community Engagement and Artistic Integrity while Creating a Dramaturg-Driven Documentary Play, In Print: The Seattle Public Library Introduction, The Seattle Public Library: A Conversation, Dramaturgy as Catalyst: A Rockies Dramaturg Driven Project, and American Playwrights and Playwriting. Issue editors: D.J. Hopkins, Shelley Orr, Madeleine Oldhamhttps://soundideas.pugetsound.edu/lmdareview/1033/thumbnail.jp

MicroRNA profiling reveals marker of motor neuron disease in ALS models

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder marked by the loss of motor neurons (MNs) in the brain and spinal cord, leading to fatally debilitating weakness. Because this disease predominantly affects MNs, we aimed to characterize the distinct expression profile of that cell type to elucidate underlying disease mechanisms and to identify novel targets that inform on MN health during ALS disease time course. microRNAs (miRNAs) are short, noncoding RNAs that can shape the expression profile of a cell and thus often exhibit cell-type-enriched expression. To determine MN-enriched miRNA expression, we used Cre recombinase-dependent miRNA tagging and affinity purification in mice. By defining thein vivomiRNA expression of MNs, all neurons, astrocytes, and microglia, we then focused on MN-enriched miRNAs via a comparative analysis and found that they may functionally distinguish MNs postnatally from other spinal neurons. Characterizing the levels of the MN-enriched miRNAs in CSF harvested from ALS models of MN disease demonstrated that one miRNA (miR-218) tracked with MN loss and was responsive to an ALS therapy in rodent models. Therefore, we have used cellular expression profiling tools to define the distinct miRNA expression of MNs, which is likely to enrich future studies of MN disease. This approach enabled the development of a novel, drug-responsive marker of MN disease in ALS rodents.SIGNIFICANCE STATEMENTAmyotrophic lateral sclerosis (ALS) is a neurodegenerative disease in which motor neurons (MNs) in the brain and spinal cord are selectively lost. To develop tools to aid in our understanding of the distinct expression profiles of MNs and, ultimately, to monitor MN disease progression, we identified small regulatory microRNAs (miRNAs) that were highly enriched or exclusive in MNs. The signal for one of these MN-enriched miRNAs is detectable in spinal tap biofluid from an ALS rat model, where its levels change as disease progresses, suggesting that it may be a clinically useful marker of disease status. Furthermore, rats treated with ALS therapy have restored expression of this MN RNA marker, making it an MN-specific and drug-responsive marker for ALS rodents.</jats:p

LMDA\u27s 20th Aniversary 1985-2005: Celebrating the First Twenty Years

Contents include: Introduction: Only the Beginning..., A Brief History of LMDA, LMDA Canada - A History, Being There: Chance Memories of a Kitchen Dog, Interviews with the Past Presidents of LMDA, The LMDA Lifetime Achievement Award: Portraits of the Lessing Award, The Elliott Hayes Award: A Thumbprint History, LMDA\u27s Residency Programs, LMDA: A Living Chronology, Afterward: Looking Forward to Looking Ahead

LMDA Review, volume 11, issue 1

Contents include: Advocacy Guidelines,LMDA Members Meet with the NEA, Update The Elliot Hayes Award,Update Script Exchange, Presentation Of Elliott Hayes Award to Rebecca Rugg, To Lynn Thomson, Conference Panels and Sessions, Conversations About Digital Dramaturgy, Key Note, Dramaturg As Generator, Multi-Authorship: Too Many Cooks?, Desperately Seeking Research, On Copyright, The Dramaturg As Advocate For The Arts On City, State/Provincial, And National Levels, Entrances And Exits, The (New Play) Workshop\u27s The Thing, Anne Cattaneo On Commissioning New Work, LMDA Regions And VPs, News From Canada, News from Baltimore, News from Chicago, The Past Two Years, and On, Notes to Fellow LMDA Members, Spotlight on Early Career Dramturgs, Dramaturgy Opening Arena Stage, Internship at the Women\u27s Project, Literary Residency in New York, Dramaturgy/Literary Management Internship at Arena Stage, Job Opening at UCSD, A Note to LMDA Members, Unity Fest 2001 Call for Scripts, Call for Directors, Actors, Dramaturgs, and Call for Updates to the LMDA Guide to Programs in Dramaturgy.https://soundideas.pugetsound.edu/lmdareview/1022/thumbnail.jp